|Videos|May 23, 2022
ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy
Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Advertisement
Advertisement
Trending on CancerNetwork
1
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
2
DREAMM-7 Study Design and the Rationale
3
From Accelerated Approval to Reapproval of Belantamab Mafodotin
4
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
5